SOPHiA GENETICS SA

NasdaqGS SOPH

SOPHiA GENETICS SA Shareholders' Equity for the year ending December 31, 2023: USD 151.44 M

SOPHiA GENETICS SA Shareholders' Equity is USD 151.44 M for the year ending December 31, 2023, a -24.33% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

SOPHiA GENETICS SA Shareholders' Equity for the year ending December 31, 2022 was USD 200.13 M, a -27.33% change year over year.
SOPHiA GENETICS SA Shareholders' Equity for the year ending December 31, 2021 was USD 275.40 M, a 174.00% change year over year.
SOPHiA GENETICS SA Shareholders' Equity for the year ending December 31, 2020 was USD 100.51 M, a 351.67% change year over year.
SOPHiA GENETICS SA Shareholders' Equity for the year ending December 31, 2019 was USD 22.25 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGS: SOPH

SOPHiA GENETICS SA

CEO	Dr. Jurgi Camblong M.B.A., Ph.D.
IPO Date	July 23, 2021
Location	Switzerland
Headquarters	Rue du Centre 172
Employees	430
Sector	Technology
Industries Software-as-a-Service (SaaS) Telehealth

Description

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

Key trends

Past 5 years